FDA Grants Fast Track Designation to Telitacicept as a Treatment for #SLE. Telitacicept is a recombinant fusion protein of TACI receptor & the Fc domain of IgG1, inhibiting B cell activity by neutralizing BLyS and APRIL. + results at #ACR2019 https://t.co/7ndMWb2Rjf